Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox Safety in Post-Stroke Spasticity with Reduced Lung Function
NCT00076687Phase 2Completed
- Sponsor
- Allergan
- Start
- Oct 2003
- Primary completion
- Aug 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of onabotulinumtoxinA in Spasticity (3 arms), sponsored by Allergan. Primary endpoints: Forced Vital Capacity at Week 6 and Forced Expiratory Volume in 1 second at Week 6. Started Oct 2003; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
Spasticity
Beyond the preview
Go deeper on NCT00076687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00076687.